Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Pharming Group ( (PHAR) ) is now available.
On March 27, 2026, Pharming Group announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for Joenja (leniolisib) to treat activated phosphoinositide 3‑kinase delta syndrome (APDS) in adults and adolescents aged 12 and older. A final European Commission decision, expected in the second quarter of 2026, could make Joenja the first approved APDS therapy across the EU, Norway, Iceland and Liechtenstein, strengthening Pharming’s position in rare immunological disorders and potentially improving access to targeted treatment for this ultra‑rare patient population.
The CHMP recommendation is based on Phase II/III randomized, placebo‑controlled data in 31 APDS patients showing statistically significant benefits on immune dysregulation and immunodeficiency, supported by long‑term extension data in 37 patients treated for a median of three years. Joenja, already approved in the U.S., U.K., Australia, Israel and Japan, is also under review in Canada and other countries, and the expanded regulatory momentum underscores Pharming’s strategy to build a global franchise in APDS and related primary immunodeficiencies.
The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
The score is driven primarily by improving financial performance (return to profitability and stronger cash generation) and a constructive earnings-call outlook (raised revenue guidance and stronger operating profit). These positives are tempered by weak technical momentum and a relatively high P/E with no dividend support.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on rare, debilitating and life‑threatening diseases, developing and commercializing a portfolio of innovative small‑molecule and biologic therapies. Headquartered in Leiden, the Netherlands, the company serves patients in more than 30 markets across North America, Europe, the Middle East, Africa and Asia‑Pacific.
Average Trading Volume: 30,000
Technical Sentiment Signal: Buy
Current Market Cap: $1.15B
See more data about PHAR stock on TipRanks’ Stock Analysis page.